[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[@QueenBioInvest](/creator/twitter/QueenBioInvest)
"Nobel day for immune tolerance Congrats to Mary Brunkow Fred Ramsdell (co-founder & former CSO at Sonoma Biotherapeutics) and Shimon Sakaguchi. Public plays on Tregs/tolerance: $COYA (LD-IL-2/Treg-enhancing) $SGMO (CAR-Treg TX200) $TLSA (intranasal anti-CD3 to induce Tregs)"  
[X Link](https://x.com/QueenBioInvest/status/1975251400742584815) [@QueenBioInvest](/creator/x/QueenBioInvest) 2025-10-06T17:26Z XXX followers, 3612 engagements


"@NextTradeX Yes but different tech. Orbital is in-vivo CAR-T with circular RNA delivered by LNPs (preclin). $IPSC develops allogeneic iPSC-derived NK/T cells ex-vivo now pivoting to autoimmune (CD19). Same immune reset theme different modality and risk. $BMY buying platform optionality"  
[X Link](https://x.com/QueenBioInvest/status/1976609274156703999) [@QueenBioInvest](/creator/x/QueenBioInvest) 2025-10-10T11:22Z XXX followers, XXX engagements


"@NextTradeX no one knows which modality wins. Thats why I size small and wait for proof. $IPSC may be cheap but it still needs clinical traction in autoimmune and clean mfg. Ill buy capitulation and treat $BMY/Orbital as a sector tailwind not a 1:1 read-through"  
[X Link](https://x.com/QueenBioInvest/status/1976631519905980470) [@QueenBioInvest](/creator/x/QueenBioInvest) 2025-10-10T12:50Z XXX followers, XXX engagements